Conference

Pre ICPR Events

About

Conference

Pre ICPR Events

About

Elliot Marseille, DrPH, MPP

University of California San Francisco & University of California Berkeley

Speaker Bio

Dr. Elliot Marseille, DrPH, MPP is the Founding Director of UC Berkeley’s Collaborative for the Economics of Psychedelics (CEP), and Principal of the firm Health Strategies International. He has 35 years of senior public health management and research experience and has published widely on the economics of global health interventions. He is the Co-Director of the Cost-Effectiveness Analysis in Medicine and Public Health course at UCSF.

Dr. Marseille is a leading expert on the economics of the emerging psychedelic-assisted therapies. He consulted with the Multidisciplinary Association for Psychedelic Studies (MAPS) on the economics of MDMA-assisted psychotherapy for the treatment of PTSD. Among other projects, he and the larger CEP team consult with the Usona Institute on the cost-effectiveness of psilocybin-assisted therapy to treat major depression; and with John Hopkins University on the cost-effectiveness of psilocybin-assisted therapy for tobacco cessation. CEP aims to make these and other analytic tools available as a public good to qualified researchers. Dr. Marseille’s additional interests include exploring the ethical foundations of cost-effectiveness analysis and identifying sound criteria for judging cost-effectiveness.

ICPR 2024 Abstract

Economics of Psychedelic Assisted Therapies: Recent Findings, Extensions, and Implications for Access

Our field now rests on a substantial and expanding bedrock of clinical efficacy and safety data. Yet, the full transformative potential of psychedelic therapies for public health hinges on a crucial factor: Affordability and cost-effectiveness. Payers' perception of value for money will dictate the extent of access to these groundbreaking interventions, and by extension, their impact on the mental and behavioral health crises in the United States. Insufficient attention has also been paid to estimating the potential impact of psychedelic therapies, as they scale up, on the epidemics of mental health and behavioral health disorders in the United States. Our group, the UC Berkeley Collaborative for The Economics of Psychedelics, aims to address these deficits. 

This presentation will delve into pressing economic questions, crucial for the adoption of these therapies by third-party payers and for access at scale. We review the current, updated findings on the economics of MDMA for PTSD including the role of group therapy, results on the economics of psilocybin for major depression, the extension of both analyses to include societal productivity benefits i.e., the enhanced economic output as symptoms of PTSD or depression are resolved or decline. We will also present early results on the economics of psilocybin-assisted therapy for smoking cessation.

We will close with an overview of the future agenda for economic analysis, next steps for our group at Berkeley, and for the field more broadly.


© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands
© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands
© 2007-2024 ICPR by OPEN Foundation, Amsterdam, the Netherlands